Skip to main content Skip to search Skip to main navigation

PIC/S: Final guideline on Data Management and Integrity

After five years of drafting, PIC/S has now published the final version of a new guideline on data integrity, the PIC/S Guidance on Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1). The document has already been applied in practice on a trial basis during this time and has been modified twice.

The resulting feedback was incorporated in the final version. Although the document is primarily addressed to inspectors, it is of course of interest to all pharmaceutical manufacturers. The document came into force on 1 July 2021.

With its remarkable 63 pages, the document covers all aspects that are to be taken into account in the handling of data in the GMP/GDP field. From basic principles, such as the ALCOA principle, to considerations for paper-based or computerised systems or the handling of so-called "findings" and potential risks, all areas are covered.Outsourcing activities and resulting actions such as audits, secure supply chain considerations or document verifications are discussed in a separate section. This also applies to necessary regulatory interventions: Possible "deficiencies" in data management are categorised and suggestions are made on how to address them. A comprehensive glossary concludes the document.


Source:
PIC/S: Q&A on Data Management and Integrity

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA: Latest Report on the International GMP Inspection Programme for API Manufacturers

EMA has published a new report on the International Active Pharmaceutical Ingredient Inspection Programme, covering the period 2017–2024. During this time, the number of participating authorities increased from ten to 13. Information was shared on 936 inspected sites and 1,684 inspections.
Read more
News: EMA

EMA Updates Procedure for Coordinating GMP Inspections

EMA has updated its procedure for coordinating GMP inspections for centrally authorised medicinal products. Version 3 has applied since 10 September 2026 and replaces Version 2. The document forms part of the Compilation of Union Procedures on Inspections and Exchange of Information (CoUP), which comprises the EU procedures and templates for GMP and GDP inspections.
Read more
Swissmedic Updates Guidance on GMP Compliance of Foreign Manufacturers

Swissmedic Updates Guidance on GMP Compliance of Foreign Manufacturers

Swissmedic has revised its guidance document “GMP compliance by foreign manufacturers”. The new Version 7.0 has been valid since 7 September 2026. In particular, it introduces new provisions for demonstrating the GMP compliance of manufacturers inspected by the US FDA. 
Read more
Swissmedic Updates Requirements for Cooperation with Pre-Wholesalers

Swissmedic Updates Requirements for Cooperation with Pre-Wholesalers

Swissmedic has revised its Technical Interpretation “Market release and distribution in cooperation with a pre-wholesaler”. The document addresses market release and distribution where a Marketing Authorisation Holder works with a pre-wholesaler (logistics and distribution service provider).
Read more
News: Europe

IPEC Updates Two Guides on Pharmaceutical Excipients

The IPEC Federation has updated two key guides on pharmaceutical excipients. The IPEC Composition Guide for Pharmaceutical Excipients (Version 3, 2026) describes an approach for manufacturers to establish excipient composition profiles. The revised version now covers biotechnology- and fermentation-derived excipients, provides further details on component types and physicochemical characterisation, and includes an example composition profile template.
Read more
Question of the Week | GMP-Verlag

What are the General Requirements for Standard Documents?

Here's the answer:
Read more
Previous
Next